Measuring Outcomes in Psoriatic Arthritis

Ogdie, Alexis; Coates, Laura C.; Mease, Philip J.

doi:10.1002/acr.24242

Cited by 18 publications

(21 citation statements)

References 125 publications

(214 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Health-related quality of life (HRQoL) was assessed through the 36-Item Short Form Survey (SF-36), Short-Form 12 (SF-12), Dermatology life Quality Index (DLQI), Euro-Qol 5 domain (EQ-5D), Psoriatic Arthritis Quality of Life (PsAQoL) and/or Ankylosing spondylitis quality of life score(ASQoL). (5,13,17,23,24) Then, we collected the domains considered important in the core set, i.e., economic cost, emotional well-being, participation (work, leisure and social activities) and structural damage. Finally, other outcomes of importance to patients and included in the OMERACT research agenda, were collected, i.e., independence, sleep, stiffness and treatment burden.…”

Section: Clinical Outcomesmentioning

confidence: 99%

“…Composite scores were collected: MDA, Very Low Disease Activity (VLDA), Disease Activity Index for Psoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score (DAS28 CRP/EULAR response), and ACR response, and Arithmetic Mean of the Desirability Function (AMDF). (5,13,17,23,24)…”

Section: Clinical Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients

Aouad

Moysidou

Rakotozafiarison

et al. 2021

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Section: Clinical Outcomesmentioning

confidence: 99%

Section: Clinical Outcomesmentioning

confidence: 99%

Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients

Aouad

Moysidou

Rakotozafiarison

et al. 2021

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

“…As of 2016, the US Food and Drug Administration (FDA) has encouraged the use of patient preferences on acceptable risk–benefit profiles and disease impacts in new drug applications to ensure patients find new treatments acceptable. As new therapies to treat PsA become available, and in light of research indicating respondents’ unmet needs, clinicians may need to adopt more personalized approaches to patient care to ensure that respondents are achieving the best possible outcomes [ 38 ]. We found that most respondents in this study preferred once-daily oral dosing, although mode of administration was not a high priority to many respondents when considering treatment options.…”

Section: Discussionmentioning

confidence: 99%

Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction: Despite recent advances in treatment for psoriatic arthritis (PsA), many patients experience inadequate response or intolerance to therapy, indicating that unmet treatmentrelated needs remain. To further characterize these unmet needs, we evaluated patients' experiences regarding the burden of PsA symptoms and disease impacts, and patients' preferences for treatment. Methods: Patients from ArthritisPower, a rheumatology research registry, completed a web-based survey. Object case best-worst scaling (BWS) was used to evaluate the relative burden of 11 PsA-related symptoms and the relative importance of improvement in nine PsA-related disease impacts. BWS data were analyzed using a random-parameters logit model. Patient demographics, preferences for mode and frequency of therapy, and preferences for methotrexate were analyzed descriptively. Results: Among the 332 participants, most were White (94%), female (80%), with mean age of 54 years (SD 11.4). In the BWS, joint pain was the most bothersome symptom, followed by other musculoskeletal pain and fatigue. The BWS for disease impacts found that improvements in the ability to perform physical activities were most important, followed by improvements in the ability to function

show abstract

“…Additionally, patients with consistently normal CRP levels over time have generally been found to have milder disease or less structural damage over time [ 16 ]. Finally, using data from randomized controlled trials, CRP levels may also be useful for assessing therapeutic response in PsA, though these data are limited [ 3 , 12 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…There is relative uncertainty surrounding its reliability, validity as a marker of disease activity, and its prognostic value. Despite this uncertainty, CRP testing is a part of several key composite outcome measures, including the American College of Rheumatology Response Criteria, the primary outcome in PsA clinical trials, and the Disease Activity of Psoriatic Arthritis (DAPSA) score, as well as rheumatoid arthritis outcome measures commonly employed in PsA (i.e., Disease Activity Score-28 [DAS28]) [ 3 ]. There is wide variability in the use of CRP across physicians monitoring psoriatic disease, including in PsA management, and variable ability to have laboratory values at the time of the clinic visit.…”

Section: Introductionmentioning

confidence: 99%

Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe

Ogdie¹,

Tillett

Booth

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

Introduction: C-reactive protein (CRP) is an important non-specific marker of both acute and chronic inflammation and can be elevated in patients with psoriatic arthritis (PsA). However, the use of CRP testing in the management of PsA can vary. This study investigated how CRP testing is implemented in real-world clinical practice for disease management of PsA. Methods: A point-in-time survey of rheumatologists and dermatologists and their next six consulting patients with PsA was conducted in France, Germany, Italy, Spain, UK (EU5), and the USA between June and August 2018. Use of CRP testing was obtained by asking the physician to state (yes/no) whether CRP was used to aid PsA diagnosis and/or to monitor the patient's disease activity. The number of CRP tests conducted in the last 12 months for each patient enrolled was provided. Results: Data were collected for 2270 patients (USA, n = 595; EU5, n = 1675). In the EU5, CRP testing was conducted to aid diagnosis in 78.7% of patients (vs. 43.4% in USA) and CRP was used to monitor disease activity in 72.0% (vs. 34.6% in USA). The majority (80.9%) of patients in the EU5 had at least one CRP test in the last 12 months compared to 42.9% in the USA. Patients treated by rheumatologists (vs. dermatologists) were at least 50% more likely to have CRP tested for monitoring purposes, this difference being most pronounced in the USA. In the EU5, CRP testing was conducted a mean ± standard deviation of 2.7 ± 1.7 times during the last 12 months, versus 2.0 ± 1.4 in the USA. Conclusions: CRP was more commonly used for the diagnosis and monitoring of PsA in Europe compared to the USA and was more commonly ordered by rheumatologists than dermatologists. In the absence of a better serum biomarker of inflammation, more data are needed to understand how CRP testing should be used in the diagnosis and management PsA.

show abstract

Measuring Outcomes in Psoriatic Arthritis

Cited by 18 publications

References 125 publications

Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients

Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients

Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry

Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe

Contact Info

Product

Resources

About